Status of PPI Use in Patients with GERD
| Total | GERD diagnosed with endoscopy | GERD diagnosed without endoscopy | p-value |
p-value |
||
|---|---|---|---|---|---|---|
| ERD | NERD | |||||
| PPI prescription rate | ||||||
| Total | 17,806 | 1,327 | 1,520 | 14,959 | <0.0001 |
<0.0001 |
| Dexlansoprazole | 294 (1.65) | 19 (1.43) | 28 (1.84) | 247 (1.65) | ||
| Esomeprazole | 10,063 (56.51) | 761 (57.35) | 885 (58.22) | 8,417 (56.27) | ||
| Ilaprazole | 350 (1.97) | 74 (5.58) | 22 (1.45) | 254 (1.70) | ||
| Lansoprazole | 759 (4.26) | 108 (8.14) | 60 (3.95) | 591 (3.95) | ||
| Omeprazole | 424 (2.38) | 28 (2.11) | 52 (3.42) | 344 (2.30) | ||
| Pantoprazole | 500 (2.81) | 59 (4.45) | 51 (3.36) | 390 (2.61) | ||
| Rabeprazole | 2,766 (15.53) | 227 (17.11) | 333 (21.91) | 2,206 (14.75) | ||
| Non-PPI | 2,650 (14.88) | 51 (3.84) | 89 (5.86) | 2,510 (16.78) | ||
| PPI prescription method | ||||||
| Total | 18,010 | 1,349 | 1,552 | 15,109 | <0.0001 |
<0.0001 |
| PPI (single) | 13,869 (77.01) | 1,094 (81.10) | 1,143 (73.65) | 11,632 (76.99) | ||
| Prokinetics (single) | 411 (2.28) | 4 (0.30) | 5 (0.32) | 402 (2.66) | ||
| PPI+Prokinetics (combination) | 742 (4.12) | 72 (5.34) | 164 (10.57) | 506 (3.35) | ||
| PPI+Prokinetics+ gastric mucosal protection (antacid) (combination) |
512 (2.84) | 80 (5.93) | 120 (7.73) | 312 (2.06) | ||
| PPI+ gastric mucosal protection (antacid) (combination) |
215 (1.19) | 31 (2.30) | 36 (2.32) | 148 (0.98) | ||
| H2 receptor blocker (single) | 1,262 (7.01) | 17 (1.26) | 24 (1.55) | 1,221 (8.08) | ||
| Others | 999 (5.55) | 51 (3.78) | 60 (3.87) | 888 (5.88) | ||
Explanation: Number of subjects (percentage of subjects).
ERD, erosive reflux disease; NERD, nonerosive reflux disease; GERD, gastroesophageal reflux disease; PPI, proton pump inhibitors.
aERD vs. NERD: Pearson's chi-square testc; bERD vs. NERD vs. GERD diagnosed with symptoms only: Pearson's chi-square testd.